# Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

> **NCT00928252** · PHASE1,PHASE2 · COMPLETED · sponsor: **Queen's Medical Center** · enrollment: 25 (actual)

## Conditions studied

- Hormone Refractory Prostate Cancer

## Interventions

- **DRUG:** IV fluorine-18 labeled methylcholine before PET/CT

## Key facts

- **NCT ID:** NCT00928252
- **Lead sponsor:** Queen's Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-08-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00928252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00928252, "Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00928252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*